PR1 leukemia peptide vaccine

PR1 leukemia peptide vaccine is a synthetic nonameric HLA-A2-restricted peptide derived from the myeloid leukemia-associated antigens proteinase 3 and neutrophil elastase. It is designed to stimulate the host immune system by inducing cytotoxic T lymphocyte (CTL) responses specifically against tumor cells expressing proteinase 3. This targeted immune response leads to lysis of malignant cells in patients with myeloid leukemias such as acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndrome (MDS). Clinical studies have shown that vaccination with the PR1 peptide can induce specific immunity correlating with clinical responses, including molecular remission in these diseases[2][3][5]. The primary mechanism involves presentation of the antigenic epitope on HLA-A2 molecules on leukemic cells, which are then recognized and killed by activated CTLs[2][8].

Other names

PR1 leukemia peptide vaccinePR-1 leukemia peptide vaccinePR 1 leukemia peptide vaccinePR1 peptide vaccinePR-1 peptide vaccinePR 1 peptide vaccinePR1PR-1PR 1